Polycyclo Ring System Having The Diazole Ring As One Of The Cyclos Patents (Class 514/393)
Benzo fused at 4,5-positions of the diazole ring (Class 514/394)
  • HEPATITIS C VIRUS INHIBITORS
    Publication number: 20110250172
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: April 8, 2011
    Publication date: October 13, 2011
    Inventors: Yao-Ling Qiu, Ce Wang, Xiaowen Peng, Yat Sun Or
  • BIARYL-SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA 2C ADRENERGIC RECEPTOR MODULATORS
    Publication number: 20110251207
    Abstract: In its many embodiments, the present invention provides a novel class of biaryi spiroaminooxazoline analogues as modulators of ?2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the ?2C adrenergic receptors using such compounds or pharmaceutical compositions.
    Type: Application
    Filed: October 6, 2009
    Publication date: October 13, 2011
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Kevin D. McCormick, Li Dong, Christopher W. Boyce, Manuel de Lera Ruiz, Salem Fevrier, Jie Wu, Junying Zheng, Younong Yu, Jianhua Chao, Walter S. Won, Ashwin U. Rao, Rongze Kuang, Pauline C. Ting, Xianhai Huang, Ning Shao, Adandan Palani, Michael Y. Berlin, Robert G. Aslanian
  • Novel Compounds
    Publication number: 20110245310
    Abstract: The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts or solvates thereof, processes for their preparation, pharmaceutical compositions containing these compounds, and their use in the treatment of allergic disorders, such as allergic rhinitis and asthma.
    Type: Application
    Filed: December 16, 2009
    Publication date: October 6, 2011
    Inventors: Ian Baxter Campbell, Simon Peace, John Martin Pritchard, Daniel Tape, Robert Charles Wheeler
  • N-METHYLPURINE DNA GLYCOSYLASE AND POLYMERASE BETA AS BIOMARKERS FOR ALKYLATOR CHEMOTHERAPY POTENTIATION
    Publication number: 20110245309
    Abstract: Described herein is the finding that polymerase ? (Pol?) and N-methylpurine DNA glycosylase (MPG) can be used as biomarkers to evaluate the sensitivity of a subject to combination therapy that includes treatment with either temozolomide (TMZ) and methoxyamine, or TMZ and a poly(ADP-ribose) polymerase (PARP) inhibitor. Thus, provided herein is a method of determining if a subject will be sensitive to TMZ and methoxyamine, or TMZ and a PARP inhibitor by measuring expression of Pol? and MPG in a sample from the subject and comparing expression of Pol? and MPG in the sample to a control. A decrease in expression of Pol? and an increase in expression of MPG relative to the control indicates the subject is sensitive to TMZ and methoxyamine, or sensitive to TMZ and the PARP inhibitor.
    Type: Application
    Filed: March 31, 2011
    Publication date: October 6, 2011
    Inventors: ROBERT W. SOBOL, JR., JIANGBO TANG
  • Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
    Patent number: 8029808
    Abstract: The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an ?-2-macroglobulin (?2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an ?2M preparation is administered in conjunction with a non-vaccine treatment modality for the treatment of cancer or infectious diseases. In the practice of the invention, a preparation comprising HSPs such as but not limited to, hsp70, hsp90 and gp96 alone or in combination with each other, noncovalently or covalently bound to antigenic molecules or ?2M, noncovalently or covalently bound to antigenic molecules is administered in conjunction with a non-vaccine treatment modality.
    Type: Grant
    Filed: April 6, 2009
    Date of Patent: October 4, 2011
    Assignee: University of Connecticut
    Inventor: Pramod K. Srivastava
  • DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-alpha]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES
    Publication number: 20110224188
    Abstract: Derivatives of 6,7-dihydro-5H-imidazo[1,2-?]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.
    Type: Application
    Filed: November 20, 2008
    Publication date: September 15, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Antonio Jose del Moral Barbosa, Joerg Martin Benzien, Steven Richard Brunette, Zhidong Chen, Derek Cogan, Donghong A. Gao, Alexander Heim-Riether, Joshua Courtney Horan, Jennifer A. Kowalski, Michael David Lawlor, Rene Marc Lemieux, Weimin Liu, Bryan Mckibben, Craig Andrew Miller, Neil Moss, Matt Aaron Tschantz, Zhaoming Xiong, Hui Yu, Yang Yu
  • Imidazoisoindole Neuropeptide S Receptor Antagonists
    Publication number: 20110212941
    Abstract: The present invention is directed to imidazoisoindole compounds which are antagonists of neuropeptide S receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which the neuropeptide S receptor is involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the neuropeptide S receptor is involved.
    Type: Application
    Filed: November 3, 2009
    Publication date: September 1, 2011
    Inventors: Peter J. Manley, Kausik K. Nanda, B. Wesley Trotter
  • Bis-heterocyclic imidazolyl compounds
    Patent number: 8008334
    Abstract: The patent application relates to new heterocyclic compounds of the general formula (I) in which R, R1, R2, R3, R4 and n have the definitions elucidated in more detail in the description, to a process for preparing them and to the use of these compounds as medicaments, particularly as aldosterone synthase inhibitors.
    Type: Grant
    Filed: December 8, 2006
    Date of Patent: August 30, 2011
    Assignee: Novartis AG
    Inventors: Peter Herold, Robert Mah, Vincenzo Tschinke, Michael Quirmbach, Christiane Marti, Aleksandar Stojanovic, Stefan Stutz
  • QUINOLINE INHIBITORS OF TYROSINE KINASE
    Publication number: 20110195066
    Abstract: The present invention relates to new quinoline inhibitors of tyrosine kinases, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: February 3, 2011
    Publication date: August 11, 2011
    Applicant: AUSPEX PHARMACEUTICALS, INC.
    Inventor: Chengzhi Zhang
  • HEPATITIS C VIRUS INHIBITORS
    Publication number: 20110189129
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: Q-G-A-L-B—W??(I), which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: January 25, 2011
    Publication date: August 4, 2011
    Inventors: Yao-Ling Qiu, Ce Wang, Xiaowen Peng, Lu Ying, Hui Cao, Yat Sun Or
  • Mazindol Combination In The Treatment Of Attention-Deficit/Hyperactivity
    Publication number: 20110183009
    Abstract: The present invention relates to the field of human health, and more particularly to the treatment of attention deficit/hyperactivity disorder (ADHD) with mazindol. The latter can be administered as monotherapy or in combination with one or more compounds, including psychostimulants, for the indication of ADHD and associated or co-morbid symptoms.
    Type: Application
    Filed: April 5, 2011
    Publication date: July 28, 2011
    Applicant: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
    Inventor: Eric Konofal
  • Methods for Treating Glioblastoma
    Publication number: 20110178046
    Abstract: Described are methods for treating cancers, e.g., glioblastoma, including administering an inhibitor of Notch signalling, e.g., a gamma secretase inhibitor, in combination with a chemotherapeutic agent.
    Type: Application
    Filed: November 10, 2010
    Publication date: July 21, 2011
    Applicant: UNIVERSITY OF MASSACHUSETTS
    Inventors: Alonzo H. Ross, Candace Gilbert, Richard Moser
  • METHODS AND COMPOSITIONS FOR TREATING URINARY TRACT INFECTIONS USING AGENTS THAT MIMIC OR ELEVATE CYCLIC AMP
    Publication number: 20110171195
    Abstract: Methods and compositions are provided for treating a urinary tract infection (UTI). The methods involve administering to a subject in need thereof a cAMP elevator or agent that mimics cAMP, particularly a labdane diterpene such as forskolin or a derivative or analog thereof in a therapeutically effective amount to treat a UTI. The methods may further include administration of at least one cAMP elevator in combination with one or more additional active compounds from other classes of therapeutic agents, such as antimicrobial agents or cholesterol lowering drugs. Compositions of the invention include pharmaceutical compositions and kits for treating a UTI in a subject in need thereof that include therapeutically effective amounts of at least two cAMP elevators, particularly where one of the cAMP elevators is a labdane diterpene such as forskolin or a derivative or analog thereof.
    Type: Application
    Filed: June 12, 2008
    Publication date: July 14, 2011
    Applicant: Duke University
    Inventors: Soman N. Abraham, Brian L. Bishop, Matthew J. Duncan, K. Ranga Rama Krishnan, Jeongmin Song, Guojie Li, David A. Zaas
  • EGFR AND PTEN GENE ALTERATIONS PREDICTS SURVIVAL IN PATIENTS WITH BRAIN TUMORS
    Publication number: 20110166409
    Abstract: The invention relates to methods of predicting the clinical outcome of brain cancer patients based on the LOH levels of the PTEN gene and on the expression levels or the polysomy/amplification levels of EGFR gene in a sample from said patients.
    Type: Application
    Filed: December 7, 2010
    Publication date: July 7, 2011
    Inventors: Michael J. Donovan, Anna Colomer Valero, Nadina Erill Sagales, Isidre Ferrer Abizanda, Susana Boluda Casas
  • METHODS OF TREATING VASOMOTOR SYMPTOMS
    Publication number: 20110152288
    Abstract: The present invention relates to methods for treating, preventing or controlling vasomotor symptoms such as hot flashes comprising administering specific norepinephrine/serotonin reuptake inhibitors.
    Type: Application
    Filed: March 4, 2009
    Publication date: June 23, 2011
    Inventor: Lawrence Wennogle
  • DISSOLVABLE DIETARY SUPPLEMENT STRIP AND METHODS FOR USING THE SAME
    Publication number: 20110150968
    Abstract: A strip, which is both edible and dissolvable, is provided comprising a film and a dosage of at least 2% of the reference daily intake (RDI) of at least one dietary supplement for malnutrition or to prevent/treat alcohol induced hangovers. A method for treating malnutrition and/or preventing and treating alcohol-induced hangovers using a dissolvable orally administered strip.
    Type: Application
    Filed: June 18, 2010
    Publication date: June 23, 2011
    Inventor: Alessandra Grassi
  • THERAPEUTIC COMBINATIONS FOR USE IN NEOPLASIA
    Publication number: 20110152206
    Abstract: The invention features compositions and methods that are useful for the treatment of neoplasia (e.g., breast cancer) by increasing DNA damage and reducing base excision repair (BER).
    Type: Application
    Filed: June 29, 2009
    Publication date: June 23, 2011
    Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Satya Narayan, Aruna S. Jaiswal, David A. Ostrov
  • USE OF CNS PENETRATING ANTICANCER COMPOUNDS FOR THE TREATMENT OF PROTOZOAL DISEASES
    Publication number: 20110118199
    Abstract: The present invention relates to the treatment of protozoal diseases by administering cytotoxic and/or cytostatic compounds, in particular those used in anticancer therapy, to patients. In particular, the invention relates to the use of anticancer agents that can penetrate into the CNS for treatment of late stage African sleeping sickness or cerebral malaria.
    Type: Application
    Filed: January 11, 2007
    Publication date: May 19, 2011
    Inventor: Matthias Dormeyer
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEOPLASIA
    Publication number: 20110110958
    Abstract: The invention provides compositions and methods for the treatment of neoplasias that are cytotoxic to neoplastic cells or that modulate JAZ expression, subcellular localization, or biological activity.
    Type: Application
    Filed: September 11, 2008
    Publication date: May 12, 2011
    Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION
    Inventors: Jingxin Qiu, Mingli Yang, David A. Ostrov, W. Stratford May
  • Heterocycle compounds
    Patent number: 7939528
    Abstract: The present invention relates to novel compounds which are antagonist or inverse agonists at an opioid receptor. Such compounds are useful in the treatment of obesity and related diseases and/or conditions in mammals, particularly humans. Methods of making and using such compounds are also disclosed.
    Type: Grant
    Filed: October 12, 2006
    Date of Patent: May 10, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Kevin Karl Barvian, Jason Daniel Speake, David John Cowan, Andrew Lamont Larkin, Jerzy Ryszard Szewczyk
  • Method of preparing a pharmaceutical cream and minimizing imiquimod impurity formation
    Patent number: 7939555
    Abstract: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.
    Type: Grant
    Filed: February 1, 2010
    Date of Patent: May 10, 2011
    Assignee: 3M Innovative Properties Company
    Inventors: Alexis S. Statham, Robert J. Nelson
  • Oncotherapeutic Application of Inhibitors of High-Affinity Glucose Transporters
    Publication number: 20110104249
    Abstract: The subject invention concerns materials and methods for treating oncological disorders in a person or animal using any agent or compound that inhibits uptake of glucose into a cell. The subject invention also concerns methods for inducing apoptosis and inhibiting the proliferation or survival of a cell. In one embodiment, the methods comprise administering an effective amount of an agent or compound that inhibits the activity of one or more glucose transporter proteins, such as Glut-1. An antibody that binds to and inhibits a glucose transporter protein can be used in the present methods.
    Type: Application
    Filed: August 15, 2008
    Publication date: May 5, 2011
    Applicant: University of South Florida
    Inventor: George R. Simon
  • USE OF THE COMBINATION COMPRISING TEMOZOLOMIDE AND TNF-ALPHA FOR TREATING GLIOBLASTOMA
    Publication number: 20110091375
    Abstract: Disclosed are methods of synergistically inhibiting growth of a glioma cell comprising contacting the cell with temozolomide and TNF?, or with temozolomide, TNF?, and radiation. Also disclosed are methods of synergistically inhibiting growth of a glioma in a human cancer patient comprising administering temozolomide and TNF?, or with temozolomide, TNF?, and radiation. Pharmaceutical combinations and therapeutic combinations suitable for use in the methods of the invention are also disclosed.
    Type: Application
    Filed: December 17, 2010
    Publication date: April 21, 2011
    Applicants: THE UNIVERSITY OF CHICAGO, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Ralph R. Weichselbaum, Donald W. Kufe, Bakhtiar Yamini
  • Method of treating actinic keratosis
    Patent number: 7928116
    Abstract: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.
    Type: Grant
    Filed: January 29, 2010
    Date of Patent: April 19, 2011
    Assignee: 3M Innovative Properties Company
    Inventors: Alexis S. Statham, Robert J. Nelson
  • Method of inducing cytokine biosynthesis
    Patent number: 7928117
    Abstract: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.
    Type: Grant
    Filed: January 31, 2010
    Date of Patent: April 19, 2011
    Assignee: 3M Innovative Properties Company
    Inventors: Alexis S. Statham, Robert J. Nelson
  • Reduction of imiquimod impurities in pharmaceutical creams
    Patent number: 7928118
    Abstract: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.
    Type: Grant
    Filed: February 1, 2010
    Date of Patent: April 19, 2011
    Assignee: 3M Innovative Properties Company
    Inventors: Alexis S. Statham, Robert J. Nelson
  • Use of EP4 receptor ligands in the treatment of IL-6 involved diseases
    Patent number: 7928119
    Abstract: Methods of treating IL-6 involved diseases with EP4 receptor ligands, including EP4 receptor antagonists. Assays to determine the effect of test compounds on PGE2-induced whole blood cells activation.
    Type: Grant
    Filed: November 3, 2006
    Date of Patent: April 19, 2011
    Assignee: Pfizer Inc.
    Inventors: Masato Shimojo, Kana Taniguchi
  • NANOMETER-SIZED PRODRUGS OF NSAIDs
    Publication number: 20110086073
    Abstract: The present invention describes nanoprodrugs of non-steroidal anti-inflammatory drug (NSAIDs) and nanoprodrugs of ?-lipoic acid-containing and NSAIDs. These nanoprodrugs have antioxidant properties and stimuli-responsiveness, which can be used to treat various disease conditions.
    Type: Application
    Filed: April 8, 2009
    Publication date: April 14, 2011
    Applicant: Cedars-Sinai Medical Center
    Inventors: John S. Yu, Bong Seop Lee
  • CANNABINOIDS IN COMBINATION WITH NON-CANNABINOID CHEMOTHERAPEUTIC AGENTS (E.G. SERM OR ALKYLATING AGENTS)
    Publication number: 20110086113
    Abstract: The invention relates to the use of one or more cannabinoids, particularly THC and/or CBD in combination with a non-cannabinoid chemotherapeutic agent in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumour, more particularly a glioma, more particularly still a glioblastoma multiforme (GBM). The non-cannabinoid chemotherapeutic agent may be a selective estrogen receptor modulator or an alkylating agent.
    Type: Application
    Filed: June 4, 2009
    Publication date: April 14, 2011
    Inventors: Guillermo Velasco Diez, Manuel Guzman Pastor, Mar Lorente, Sofia Torres
  • Benzimidazole derivatives and their use for modulating the GABAreceptor complex
    Patent number: 7923464
    Abstract: This invention relates to novel benzimidazole derivatives, pharmaceutical compositions containing these compounds, and methods of treatment therewith. The compounds of the invention are useful in the treatment of central nervous system diseases and disorders, which are responsive to modulation of the GABAA receptor complex, and in particular for combating anxiety and related diseases.
    Type: Grant
    Filed: December 4, 2006
    Date of Patent: April 12, 2011
    Assignee: Neurosearch A/S
    Inventors: Janus S. Larsen, Lene Teuber, Philip K. Ahring, Elsebet Østergaard Nielsen, Naheed Mirza
  • Methods for stabilizing imiquimod for two months, four months, and six months
    Patent number: 7923463
    Abstract: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.
    Type: Grant
    Filed: February 1, 2010
    Date of Patent: April 12, 2011
    Assignee: 3M Innovative Properties Company
    Inventors: Alexis S. Statham, Robert J. Nelson
  • Method of controlling formation of imiquimod impurities
    Patent number: 7919501
    Abstract: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.
    Type: Grant
    Filed: January 30, 2010
    Date of Patent: April 5, 2011
    Assignee: 3M Innovative Properties Company
    Inventors: Alexis S. Statham, Robert J. Nelson
  • Method of treating mollescum contagiosum
    Patent number: 7915279
    Abstract: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.
    Type: Grant
    Filed: January 31, 2010
    Date of Patent: March 29, 2011
    Assignee: 3M Innovative Properties Company
    Inventors: Alexis S. Statham, Robert J. Nelson
  • Method of treating genital or peri-anal warts
    Patent number: 7915277
    Abstract: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.
    Type: Grant
    Filed: January 30, 2010
    Date of Patent: March 29, 2011
    Assignee: 3M Innovative Properties Company
    Inventors: Alexis S. Statham, Robert J. Nelson
  • Method of treating basal cell carcinoma
    Patent number: 7915278
    Abstract: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.
    Type: Grant
    Filed: January 30, 2010
    Date of Patent: March 29, 2011
    Assignee: 3M Innovative Properties Company
    Inventors: Alexis S. Statham, Robert J. Nelson
  • ANTI-HEPATITIS C VIRUS AGENTS AND ANTI-HIV AGENTS
    Publication number: 20110071202
    Abstract: An anti-hepatitis C virus agent or anti-HIV agent comprising, as an active ingredient, a fullerene derivative which has a nitrogen atom forming a ring together with adjacent bonded carbon atom pairs constituting the carbon cluster skeleton of the fullerene or a quaternary amine salt thereof is provided.
    Type: Application
    Filed: November 30, 2010
    Publication date: March 24, 2011
    Inventors: Tadahiko Mashino, Kumiko Shimotohno
  • SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING MEBICAR
    Publication number: 20110070305
    Abstract: The invention relates to a sustained release pharmaceutical composition, containing mebicar, for the treatment of anxiety, depression and other psychiatric and neurological disorders.
    Type: Application
    Filed: September 24, 2009
    Publication date: March 24, 2011
    Applicant: ALPHARX INC.
    Inventors: Joseph Schwarz, Michael Weisspapir
  • Histamine H3 Inverse Agonists and Antagonists and Methods of Use Thereof
    Publication number: 20110065694
    Abstract: Provided herein are fused imidazolyl compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, including, e.g., neurological disorders and metabolic disorders. Compounds provided herein inhibit the activity of histamine H3 receptors and modulate the release of various neurotransmitters, such as, e.g., histamine, acetylcholine, norepinephrine, and dopamine (e.g. at the synapse). Pharmaceutical compositions containing the compounds and their methods of use are also provided herein.
    Type: Application
    Filed: September 9, 2010
    Publication date: March 17, 2011
    Inventors: Milan Chytil, Sharon R. Engel, Qun Kevin Fang
  • Reduction of imiquimod impurities at four months using refined oleic acid
    Patent number: 7906525
    Abstract: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.
    Type: Grant
    Filed: February 1, 2010
    Date of Patent: March 15, 2011
    Assignee: 3M Innovative Properties Company
    Inventors: Alexis S. Statham, Robert J. Nelson
  • Method of treating a dermal and/or mucosal associated condition
    Patent number: 7906526
    Abstract: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.
    Type: Grant
    Filed: February 1, 2010
    Date of Patent: March 15, 2011
    Assignee: 3M Innovative Properties Company
    Inventors: Alexis S. Statham, Robert J. Nelson
  • Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
    Patent number: 7906649
    Abstract: The present invention is directed to novel substituted aminocyclohexanes which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
    Type: Grant
    Filed: May 19, 2006
    Date of Patent: March 15, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Tesfaye Biftu, Danqing Feng, Xiaoxia Qian, Ann E. Weber, Jason Cox
  • 3,6-substituted imidazol[1,2-b]pyridazine analogs for treating allergic and inflammatory diseases
    Patent number: 7906512
    Abstract: Methods for treating an allergic or inflammatory disease or other Syk-mediated disease or Syk-mediated condition characterized by administering a composition which contains a therapeutically effective amount of a 3,6-substituted imidazol[1,2-b]pyridazine compound.
    Type: Grant
    Filed: March 10, 2010
    Date of Patent: March 15, 2011
    Assignee: Alcon, Inc.
    Inventors: Mark R. Hellberg, Steven T. Miller, Andrew Rusinko
  • Reduction of imiquimod impurities using refined oleic acid
    Patent number: 7906527
    Abstract: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.
    Type: Grant
    Filed: February 1, 2010
    Date of Patent: March 15, 2011
    Assignee: 3M Innovative Properties Company
    Inventors: Alexis S. Statham, Robert J. Nelson
  • Pharmaceutical compositions comprising polymorphic forms ?, ?, and ? of rifaximin
    Patent number: 7906542
    Abstract: Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin ? and rifaximin ?, and a poorly crystalline form referred to as rifaximin ?, useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a fixed temperature and for a fixed period of time, followed by a drying under controlled conditions until reaching a precise water content in the end product, are the object of the invention.
    Type: Grant
    Filed: May 13, 2008
    Date of Patent: March 15, 2011
    Assignee: Alfa Wassermann, S.p.A.
    Inventors: Giuseppe Claudio Viscomi, Manuela Campana, Dario Braga, Donatella Confortini, Vincenzo Cannata, Paolo Righi, Goffredo Rosini
  • Method of reducing imiquimod impurity formation
    Patent number: 7906543
    Abstract: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.
    Type: Grant
    Filed: January 29, 2010
    Date of Patent: March 15, 2011
    Assignee: 3M Innovative Properties Company
    Inventors: Alexis S. Statham, Robert J. Nelson
  • Pharmaceutical cream having similar or less levels of imiquimod impurity formation as cream with BHA (comparator)
    Patent number: 7906524
    Abstract: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.
    Type: Grant
    Filed: February 1, 2010
    Date of Patent: March 15, 2011
    Assignee: 3M Innovative Properties Company
    Inventors: Alexis S. Statham, Robert J. Nelson
  • Method of preparing a pharmaceutical cream and minimizing imiquimod impurity formation (at least four months storage)
    Patent number: 7902244
    Abstract: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.
    Type: Grant
    Filed: February 1, 2010
    Date of Patent: March 8, 2011
    Assignee: 3M Innovative Properties Company
    Inventors: Alexis S. Statham, Robert J. Nelson
  • Methods for controlling formation of imiquimod impurities for two months, four months, and six months
    Patent number: 7902246
    Abstract: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.
    Type: Grant
    Filed: February 1, 2010
    Date of Patent: March 8, 2011
    Assignee: 3M Innovative Properties Company
    Inventors: Alexis S. Statham, Robert J. Nelson
  • Method of inducing interferon biosynthesis
    Patent number: 7902211
    Abstract: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.
    Type: Grant
    Filed: February 1, 2010
    Date of Patent: March 8, 2011
    Assignee: 3M Innovative Properties Company
    Inventors: Alexis S. Statham, Robert J. Nelson
  • Method of stabilizing imiquimod
    Patent number: 7902242
    Abstract: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.
    Type: Grant
    Filed: January 30, 2010
    Date of Patent: March 8, 2011
    Assignee: 3M Innovative Properties Company
    Inventors: Alexis S. Statham, Robert J. Nelson